ScreenerHero

TECX Tectonic Therapeutic, Inc.

NAS · US · Healthcare · Biotechnology · tectonictx.com
22.71USD+1.34%Mkt Cap: 443.97M $P/E: —

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe tech…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap443.97M USD
Enterprise Value215.43M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-74.15M USD
Revenue/Share—
Last Price22.71 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees60
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.79
PEG—
EV/EBITDA-2.30
EV/Revenue—
P/S—
P/B1.83
EPS (TTM)-4.43
EPS (Forward)-4.68
52W Range
14.3933% of range39.53
52W High39.53 USD
52W Low14.39 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-29.50%
ROA-28.41%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-60.08M USD
CapEx (TTM)208.00K USD
FCF Margin—
FCF Yield-10.52%
Net Debt-222.67M USD
Net Debt/EBITDA2.38
Balance Sheet
Debt/Equity0.01
Current Ratio22.29
Quick Ratio21.90
Book Value/Sh12.24 USD
Cash/Share11.62 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateJun 21, 2024
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)76.63 USD
Upside (mean)+237.4%
Target Range60.00 USD – 93.00 USD
60.00+237.4% to mean93.00
# Analysts8
Ownership
Shares Out.19.55M
Float11.90M
Insiders37.60%
Institutions71.77%
Short Interest
Short Ratio10.2d
Short % Float22.95%
Short % Out.11.35%
Shares Short2.22M
Short (prev mo.)1.73M
Technical
SMA 5030.05 (-24.4%)
SMA 20028.00 (-18.9%)
Beta0.38
S&P 52W Chg16.45%
Avg Vol (30d)226.98K
Avg Vol (10d)315.34K
Technical Indicators
RSI (14)30.2
MACD-2.3821
MACD Signal-2.2055
MACD Hist.-0.1766
BB Upper32.11 USD
BB Middle25.87 USD
BB Lower19.63 USD
BB Width48.23%
ATR (14)1.704 USD
Vol Ratio (20d)1.21x